Basket cover image
15 handpicked stocks

Fueling Profits: Beneficiaries Of OPEC+ Production Policy

OPEC+ is expected to maintain its policy of gradually increasing oil production, aiming to stabilize global energy markets. This could lead to moderated fuel costs, creating a potential advantage for companies in sectors like transportation and manufacturing where fuel is a major expense.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juillet 25

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

UNP

Union Pacific Corporation

UNP

Current price

$223.77

VLO

Valero Energy Corp.

VLO

Current price

$137.93

PBF

PBF Energy Inc.

PBF

Current price

$23.48

About This Group of Stocks

1

Our Expert Thinking

OPEC+ is maintaining its gradual oil production increases to stabilize global energy markets. This strategic approach could lead to more predictable and potentially lower fuel costs, creating opportunities for companies where energy is a major operational expense.

2

What You Need to Know

This group focuses on fuel-intensive sectors like transportation, logistics, and energy infrastructure. These companies could see improved profit margins as moderated fuel prices reduce their operational costs, making this a tactical play on global energy policy.

3

Why These Stocks

Each company was handpicked by professional analysts based on their direct exposure to fuel costs. From refiners and pipeline operators to logistics companies, these businesses are positioned to benefit when energy expenses moderate.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+107.68%

Group Performance Snapshot

107.68%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 107.68% over the next year.

11 of 15

Stocks Rated Buy by Analysts

11 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

Energy Cost Relief

As OPEC+ stabilizes oil production, these companies could see their biggest expense category become more predictable and potentially cheaper.

📈

Margin Expansion Opportunity

Lower fuel costs flow directly to the bottom line for transportation and logistics companies, potentially boosting profit margins significantly.

🎯

Strategic Timing Play

This group captures companies positioned at the right place and time to benefit from global energy policy shifts that could reshape cost structures.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View all Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.